Table 8Effects of newer oral anticoagulants compared with adjusted-dose warfarin for venous thromboembolism

Summary Risk Ratios (95% CI)Test for HeterogeneitySummary Risk Ratios (95% CI)Test for Heterogeneity
OutcomeNon-ximelagatran studies (n = 2)All studies (n = 3)
All-cause mortality0.84 (0.59 to 1.18)Q = 0.47, I2 = 0%
p = 0.49
0.78 (0.59 to 1.02)Q = 1.01, I2 = 0%
p = 0.60
Recurrent DVT0.66 (0.37 to 1.15)Q = 1.49, I2 = 33%
p = 0.22
0.72 (0.49 to 1.06)Q = 2.02, I2 = 1%
p = 0.36
Death–thromboembolica0.56 (0.19 to 1.69)Q = 0.28, I2 = 0%
p = 0.60
NANA
Recurrent DVT/PE0.86 (0.55 to 1.33)Q = 1.79, I2 = 44%
p = 0.18
0.91 (0.67 to 1.24)Q = 2.43, I2 = 18%
p = 0.30
Adverse Effect
Discontinued due to adverse effects1.19 (0.93 to 1.51)Q = 1.43, I2 = 30%
p = 0.23
1.24 (1.10 to 1.41)Q = 1.73, I2 = 0%
p = 0.42
Major bleeding0.77 (0.49 to 1.20)Q = 0.14, I2 = 0%
p = 0.71
0.69 (0.48 to 0.99)Q = 0.91, I2 = 0%
p = 0.63
Fatal bleeding0.50 (0.12 to 2.06)Q = 0.31, I2 = 0%
p = 0.58
0.41 (0.13 to 1.35)Q = 0.59, I2 = 0%
p = 0.75
Myocardial infarction2.83 (0.75 to 10.71)Q = 0.44, I2 = 0%
p =0.51
3.46 (1.03 to 11.62)Q = 0.98, I2 = 0%
p = 0.61
Liver dysfunction0.60 (0.27 to 1.34)Q = 6.80, I2 = 85%
p = 0.009
1.20 (0.29 to 4.98)Q = 65.83, I2 = 97%
p < 0.001
a

No data for ximelagatran group.

b

Fiessenger 2005 did not report thromboembolic death

Abbreviations: DVT = deep venous thrombosis; NA = not applicable; PE = pulmonary embolism

No data for ximelagatran group.

From: RESULTS

Cover of Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism
Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism [Internet].
Adam SS, McDuffie JR, Ortel TL, et al.
Washington (DC): Department of Veterans Affairs; 2012 Apr.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.